Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Martin, Miguel Holmes, Frankie A Ejlertsen, Bent Delaloge, Suzette Moy, Beverly Iwata, Hiroji von Minckwitz, Gunter Chia, Stephen K L Mansi, Janine Barrios, Carlos H Gnant, Michael Tomašević, Zorica Denduluri, Neelima Šeparović, Robert Gokmen, Erhan Bashford, Anna Ruiz Borrego, Manuel Kim, Sung-Bae Jakobsen, Erik Hugger Ciceniene, Audrone Inoue, Kenichi Overkamp, Friedrich Heijns, Joan B Armstrong, Anne C Link, John S Joy, Anil Abraham Bryce, Richard Wong, Alvin Moran, Susan Yao, Bin Xu, Feng Auerbach, Alan Buyse, Marc Chan, Arlene